

DTL Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP10973c**Specification**

DTL Antibody (Center) - Product Information

| | |
|-------------------|------------------------------------------------------|
| Application | FC, WB,E |
| Primary Accession | O9NZJ0 |
| Other Accession | O3TLR7 , NP_057532.2 |
| Reactivity | Human, Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 79468 |
| Antigen Region | 229-256 |

DTL Antibody (Center) - Additional Information**Gene ID** 51514**Other Names**

Denticleless protein homolog, DDB1- and CUL4-associated factor 2, Lethal(2) denticleless protein homolog, Retinoic acid-regulated nuclear matrix-associated protein, DTL, CDT2, CDW1, DCAF2, L2DTL, RAMP

Target/Specificity

This DTL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 229-256 amino acids from the Central region of human DTL.

Dilution

FC~~1:10~50

WB~~1:1000

E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

DTL Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

DTL Antibody (Center) - Protein Information

Name DTL**Synonyms** CDT2, CDW1, DCAF2, L2DTL, RAMP

Function Substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex required for cell cycle control, DNA damage response and translesion DNA synthesis. The DCX(DTL) complex, also named CRL4(CDT2) complex, mediates the polyubiquitination and subsequent degradation of CDT1, CDKN1A/p21(CIP1), FBH1, KMT5A and SDE2 (PubMed:[16861906](#), PubMed:[16949367](#), PubMed:[16964240](#), PubMed:[17085480](#), PubMed:[18703516](#), PubMed:[18794347](#), PubMed:[18794348](#), PubMed:[19332548](#), PubMed:[20129063](#), PubMed:[23478441](#), PubMed:[23478445](#), PubMed:[23677613](#), PubMed:[27906959](#)). CDT1 degradation in response to DNA damage is necessary to ensure proper cell cycle regulation of DNA replication (PubMed:[16861906](#), PubMed:[16949367](#), PubMed:[17085480](#)). CDKN1A/p21(CIP1) degradation during S phase or following UV irradiation is essential to control replication licensing (PubMed:[18794348](#), PubMed:[19332548](#)). KMT5A degradation is also important for a proper regulation of mechanisms such as TGF-beta signaling, cell cycle progression, DNA repair and cell migration (PubMed:[23478445](#)). Most substrates require their interaction with PCNA for their polyubiquitination: substrates interact with PCNA via their PIP-box, and those containing the 'K+4' motif in the PIP box, recruit the DCX(DTL) complex, leading to their degradation. In undamaged proliferating cells, the DCX(DTL) complex also promotes the 'Lys-164' monoubiquitination of PCNA, thereby being involved in PCNA- dependent translesion DNA synthesis (PubMed:[20129063](#), PubMed:[23478441](#), PubMed:[23478445](#), PubMed:[23677613](#)). The DDB1-CUL4A-DTL E3 ligase complex regulates the circadian clock function by mediating the ubiquitination and degradation of CRY1 (PubMed:[26431207](#)).

Cellular Location

Nucleus. Nucleus membrane; Peripheral membrane protein; Nucleoplasmic side. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Chromosome Note=Nuclear matrix-associated protein. Translocates from the interphase nucleus to the metaphase cytoplasm during mitosis


Tissue Location


Expressed in placenta and testis, very low expression seen in skeletal muscle. Detected in all hematopoietic tissues examined, with highest expression in thymus and bone marrow. A low level detected in the spleen and lymph node, and barely detectable level in the peripheral leukocytes. RA treatment down-regulated the expression in NT2 cell.

DTL Antibody (Center) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

DTL Antibody (Center) - Images



DTL Antibody (Center) (Cat. #AP10973c) western blot analysis in mouse spleen tissue lysates (35ug/lane). This demonstrates the DTL antibody detected the DTL protein (arrow).



DTL Antibody (Center) (Cat. #AP10973c) flow cytometric analysis of HeLa cells (right histogram) compared to a negative control cell (left histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

DTL Antibody (Center) - Background

Substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex required for cell cycle control, DNA damage response and translesion DNA synthesis. The DCX(DTL) complex, also named CRL4(CDT2) complex, mediates the polyubiquitination and subsequent degradation of CDT1 and CDKN1A/p21(CIP1). CDT1 degradation in response to DNA damage is necessary to ensure proper cell cycle regulation of DNA replication. CDKN1A/p21(CIP1) degradation during S phase or following UV irradiation is essential to control replication licensing. Most substrates require their interaction with PCNA for their polyubiquitination: substrates interact with PCNA via their PIP-box, and those containing the 'K+4' motif in the PIP box, recruit the DCX(DTL) complex, leading to their degradation. In undamaged proliferating cells, the DCX(DTL) complex also promotes the 'Lys-164' monoubiquitination of PCNA, thereby being involved in PCNA-dependent translesion DNA synthesis.

DTL Antibody (Center) - References

Centore, R.C., et al. Mol. Cell 40(1):22-33(2010)
Abbas, T., et al. Mol. Cell 40(1):9-21(2010)
Song, B., et al. Mol. Cancer 9, 96 (2010) :
Li, J., et al. Br. J. Cancer 101(4):691-698(2009)

Abbas, T., et al. Genes Dev. 22(18):2496-2506(2008)